Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 7/20 | 0.53 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | CA5A | P35218 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390643 | 0.86 | ALDH1A1 (0.59) | HSD17B10CA2CA1CA12CA9 | |
| SCHEMBL1817485 | 0.84 | HSD17B10 (0.60) | HSD17B10KMT2AHSD11B1VCAM1ALDH1A1 | |
| SCHEMBL31518627 | 0.84 | HSD17B10 (0.60) | HSD17B10KMT2AHSD11B1VCAM1ALDH1A1 | |
| SCHEMBL7830990 | 0.82 | HSD17B10 (0.58) | HSD17B10KMT2AHSD11B1VCAM1ALDH1A1 | |
| SCHEMBL5082000 | 0.82 | HSD17B10 (0.58) | HSD17B10KMT2AHSD11B1VCAM1ALDH1A1 | |
| SCHEMBL7830991 | 0.81 | HSD17B10 (0.56) | HSD17B10KMT2AHSD11B1VCAM1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28240861 | 0.81 | HSD17B10 (0.56) | HSD17B10KMT2AHSD11B1VCAM1ALDH1A1 | |
| SCHEMBL29426295 | 0.80 | TDP1 (0.58) | CA2CA1CA12CA9CA5A | |
| SCHEMBL10034888 | 0.80 | GPR35 (0.56) | CA2CA1CA12CA9CA5A | |
| SCHEMBL1219754 | 0.80 | TDP1 (0.58) | CA2CA1CA12CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781197-B2 | Sulfonamide analogues of galiellalactone | GLACTONE PHARMA DEVELOPMENT AB (SE) | 2020-09-22 | — | — | US | disclosed |
| US-20200087274-A1 | SULFONAMIDE ANALOGUES OF GALIELLALACTONE | GLACTONE PHARMA DEVELOPMENT AB (SE) | 2020-03-19 | — | — | US | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-108395435-A | Triazolopyrimidine sulfonamides compound and its preparation method and application | 深圳大学 | 2018-08-14 | — | — | CN | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| CN-105585517-A | N-chloro-aryl sulphinyl sulfimide and preparation method thereof | UNIV BEIJING CHEMICAL TECH | 2016-05-18 | — | — | CN | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| CN-101006052-A | Pyrrole derivatives as pharmaceutical agents | EXELIXIS INC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1594866-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004072070-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | HSD17B10 2768/4885CA2 1737/4885CA1 2327/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | HSD17B10 2768/4885CA2 1737/4885CA1 2327/4885 |
| US-10781197-B2 | Sulfonamide analogues of galiellalactone | STAT3, STAT1, STAT5A | HSD17B10 1166/4885CA2 3636/4885CA1 3037/4885 |
| US-20200087274-A1 | SULFONAMIDE ANALOGUES OF GALIELLALACTONE | STAT3, STAT1, STAT5A | HSD17B10 1166/4885CA2 3636/4885CA1 3037/4885 |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | NCOA1, NCOA2, NCOA3 | HSD17B10 203/4885CA2 3115/4885CA1 3623/4885 |
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | MKI67, TK1, CDK2 | HSD17B10 2308/4885CA2 2313/4885CA1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.